Protein mono-ADP-ribosyltransferase PARP6 (PARP6)

Protein mono-ADP-ribosyltransferase PARP6 (PARP6) is an enzyme belonging to the poly (ADP-ribose) polymerase family, specifically classified as a mono-ADP-ribosyltransferase due to its ability to catalyze the addition of a single ADP-ribose unit to substrate proteins using NAD+ as a cofactor[2][3][7]. PARP6 is widely conserved among vertebrates and contains a characteristic PARP catalytic domain responsible for its enzymatic activity[2]. It is expressed at low levels in most tissues but is highly enriched in neuronal cells, where it regulates dendritic morphogenesis and is essential for normal neural circuit formation[3][4]. In cancer biology, PARP6 functions as a negative regulator of cell proliferation and may act as a tumor suppressor, with higher expression correlating to better prognosis in colorectal cancer[2][6]. Loss-of-function mutations in PARP6 are associated with neurodevelopmental disorders, including epilepsy, microencephaly, and intellectual disabilities, and knockout mouse studies indicate that its catalytic activity is required for survival beyond birth[4][7]. There are currently no known drugs that specifically target PARP6, but its role in cell cycle progression and tumor suppression make it an emerging target of interest in oncology and neurobiology research[6][7].

Other names

ARTD17PARP-6pART17poly [ADP-ribose] polymerase 6ADP-ribosyltransferase diphtheria toxin-like 17PARP-6-B1PARP-6-CMIEREN, class IMIEREN, class II

Inhibition of mono-ADP-ribosyltransferase activity leading to cell cycle arrest; Suppression of cell proliferation and tumorigenesis (potential tumor suppressor mechanism)